Frank Knuettel II, CEO of Chromocell Therapeutics Corp. CHRO, was recently a guest on Biedex Markets’s All-Access.
Chromocell is a clinical-stage biotech company focusing on novel pain treatments. The company’s therapeutics target a specific channel in the body, NaV1.7, known for its role in pain. By blocking it, the company aims to stop pain signals from reaching the brain and spinal cord.
Chromocell is currently specifically targeting erythromelalgia, which causes intense burning pain, redness and increased skin temperature in the feet and sometimes the hands.
Watch the full video here:
Featured photo by Hal Gatewood on Unsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
